GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroPace Inc (NAS:NPCE) » Definitions » EPS (Diluted)

NeuroPace (NeuroPace) EPS (Diluted) : $-1.27 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NeuroPace EPS (Diluted)?

NeuroPace's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.22. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.27.

NeuroPace's EPS (Basic) for the three months ended in Dec. 2023 was $-0.22. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.27.

NeuroPace's EPS without NRI for the three months ended in Dec. 2023 was $-0.22. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.27.

During the past 3 years, the average EPS without NRIGrowth Rate was 16.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, NeuroPace's highest 3-Year average EPS without NRI Growth Rate was 16.60% per year. The lowest was 10.90% per year. And the median was 13.75% per year.


NeuroPace EPS (Diluted) Historical Data

The historical data trend for NeuroPace's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroPace EPS (Diluted) Chart

NeuroPace Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
-2.70 -2.17 -2.17 -1.91 -1.27

NeuroPace Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.45 -0.41 -0.36 -0.28 -0.22

Competitive Comparison of NeuroPace's EPS (Diluted)

For the Medical Devices subindustry, NeuroPace's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroPace's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's PE Ratio distribution charts can be found below:

* The bar in red indicates where NeuroPace's PE Ratio falls into.



NeuroPace EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

NeuroPace's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-32.956-0)/25.852
=-1.27

NeuroPace's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-6.2-0)/26.810
=-0.23

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuroPace  (NAS:NPCE) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


NeuroPace EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of NeuroPace's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroPace (NeuroPace) Business Description

Traded in Other Exchanges
N/A
Address
455 N. Bernardo Avenue, Mountain View, CA, USA, 94043
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Executives
Martha Morrell officer: Chief Medical officer C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Kck Ltd. 10 percent owner CRAIGMUIR CHAMBERS, ROAD TOWN, TORTOLA D8 VG1110
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Joel Becker director, officer: Chief Executive Officer ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Uri Geiger director 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Partners Ii L.p. 10 percent owner 2875 NE 191ST, SUITE 500, AVENTURA FL 33180
Irina Ridley officer: General Counsel and Secretary C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Lisa Andrade director 6300 BEE CAVE ROAD, BLDG 2, SUITE 100, AUSTIN TX 78746
Greg Shaw Garfield director C/O SEMLER SCIENTIFIC, INC., 2330 NW EVERETT ST., PORTLAND OR 97210
Frank M Fischer director 9701 JERONIMO, IRVINE CA 92618
Evan Norton director C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Joseph Lacob director 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Renee Ryan director C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Michael Favet director, officer: Chief Executive Officer C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043